DeltaRex-G
1 clinical trial
1 product
2 abstracts
8 indications
Indication
Pancreatic CancerIndication
OsteosarcomaIndication
Malignant Peripheral Nerve Sheath TumorIndication
ChondrosarcomaIndication
Soft Tissue SarcomaIndication
ChordomaIndication
SarcomaIndication
Breast CarcinomaAbstract
Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.Org: William H. Isacoff, MD, Inc,
Clinical trial
BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastStatus:
Abstract
Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, Dornsife College of Letters, University of Southern California, Los Angeles, CA, University of California Los Angeles,